This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Elsiglutide

Helsinn Healthcare SA

Drug Names(s): ZP1846, ZP1846-TIDE, Z1846

Description: ZP1846 is a novel peptide discovered using Zealand's Pharma proprietary SIP technology. XP1846 is a GLP-2 (glucagon-like peptide-2) receptor agonist. GLP-2 is a naturally occurring hormone that regulates the growth, proliferation and maintenance of the cells lining the small intestine.

Deal Structure: Zealand and Helsinn
In December 2008, Zealand Pharma and Helsinn Healthcare announced that it hassigned a partnering agreement, for the development and worldwidecommercialization of ZP1846. Under the terms of the agreement, Helsinn Healthcare will receive a worldwide exclusive license to ZP1846 and will be responsible for all further development, regulatory approvals, manufacturing, marketing and sales of the compound either on its own or through its sub-licensees. In return Helsinn Healthcare will pay Zealand Pharma development milestones and sales milestones for an undisclosed amount. In addition, Zealand Pharma will receive royalties on future sales and Zealand Pharma has retains the marketing rights to the Nordic countries. The total value of the non royalty portion of the partnership is valued up to 140 million.

Partners: Zealand Pharma A/S


Elsiglutide News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug